Nabi Biopharmaceuticals, Kedrion to develop Civacir in hepatitis C

By Lisa Kerner

Charlotte, N.C., June 29 - Nabi Biopharmaceuticals and Kedrion SpA have agreed to develop and commercialize Civacir [Hepatitis C Immune Globulin (Human)] in Europe and the United States.

Civacir is Nabi's plasma-derived, polyclonal antibody product candidate for the prevention of the recurrence of hepatitis C-related liver disease in HCV-positive liver transplant recipients, or in patients who receive an HCV-positive liver.

Kedrion will be Nabi's exclusive licensee to commercialize Civacir in Europe.

Nabi will be paid milestone and royalty payments, while Kedrion will assume development costs through at least phase 2 clinical trials, the companies said.

"This agreement represents a major funding event for Nabi Biopharmaceuticals," chief executive officer Thomas H. McLain said in a company news release.

"It is also a validation of the clinical and commercial potential of the Civacir program."

Nabi is focused on developing products that address unmet medical needs around its core business areas of gram-positive bacterial infections, hepatitis and transplant, kidney disease (nephrology) and nicotine addiction.

Kedrion is a global biopharmaceutical company located in Lucca, Italy.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.